Introduction
============

TMC278 had a high virologic response rate, non-inferior to EFV, in two Phase III double-blind trials ECHO (TMC278-C209, NCT00540449) and THRIVE (TMC278-C215, NCT00543725) in treatment-naïve HIV-infected adult patients. As the use of NNRTIs, particularly nevirapine, has been associated with hepatic-related adverse events (AEs), especially in HIV/hepatitis B (HBV) and/or hepatitis C (HCV) co-infected patients, a subgroup analysis of these events was performed on the pooled Week 48 Phase III data.

Methods
=======

Patients (N=1368) with alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) ≤ 5x upper limit of normal received TMC278 25mg qd or EFV 600mg qd, plus TDF/FTC (ECHO) or TDF/FTC, AZT/3TC or ABC/3TC (THRIVE). HIV/HBV and/or HCV co-infection status was determined at baseline in 1335 patients by HBV surface antigen, HCV antibody and RNA testing.

Results
=======

At baseline, 112/1335 patients (8.4%) had evidence of HIV/HBV and/or HCV co-infection (randomised to TMC278, n=49: 7.3%; EFV, n=63: 9.5%). Table [1](#T1){ref-type="table"} summarises the outcomes.

Compared with HIV mono-infected patients, co-infected patients had more hepatic AEs (clinical and laboratory) and lower virologic responses, which were similar across treatment groups. Hepatic AEs rarely led to treatment discontinuation (TMC278: n=3 vs. EFV: n=9 patients). There were no fatal hepatic AEs.

                                                           *HIV/HBV and/or HCV co-infected patients*                      *HIV mono-infected patients*   
  -------------------------------------------------------- ------------------------------------------- ------------------ ------------------------------ ------------------
                                                           TMC278 25mg qd                              EFV 600mg qd       TMC278 25mg qd                 EFV 600mg qd
                                                                                                                                                         
  *Efficacy (Week 48 outcomes)\**                          N=49                                        N=63               N=621                          N=602
                                                                                                                                                         
  \% (95% CI) with viral load \<50 copies/mL, ITT-TLOVR    73.5 (60.7-86.3)                            79.4 (69.1-89.6)   85.0 (82.2-87.8)               82.6 (79.5-85.6)
                                                                                                                                                         
  Mean CD4 count (95% CI)                                  N=48                                        N=63               N=621                          N=602
                                                                                                                                                         
  Baseline, cells/mm^3^                                    230 (198-263)                               246 (216-276)      262 (251-273)                  274 (262-285)
                                                                                                                                                         
  Change from baseline, NC=F^†^, cells/mm^3^               +137 (100-175)                              +192 (147-238)     +197 (186-209)                 +173 (161-185)
                                                                                                                                                         
  Change from baseline, NC=F^†^, %                         +6.6 (5.0-8.3)                              +7.7 (6.4-9.0)     +8.6 (8.1-9.0)                 +8.4 (7.9-8.8)
                                                                                                                                                         
  *Safety^‡^, ^§^*                                                                                                                                       
                                                                                                                                                         
  *Treatment-emergent hepatic AEs of interest, n (%)*      N=54                                        N=66               N=632                          N=616
                                                                                                                                                         
  Any hepatic AE                                           15 (27.8)                                   17 (25.8)          23 (3.6)                       28 (4.5)
                                                                                                                                                         
  Hepatobiliary disorders^Â¶^                              3 (5.6)                                     7 (10.6)           6 (0.9)                        9 (1.5)
                                                                                                                                                         
  HBV or HCV reported as an AE                             3 (5.6)                                     5 (7.6)            \-                             \-
                                                                                                                                                         
  Hepatic laboratory abnormalities reported as an AE       9 (16.7)                                    8 (12.1)           19 (3.0)                       21 (3.4)
                                                                                                                                                         
  *Grade 3 to 4 hepatic laboratory abnormalities, n (%)*   N=54                                        N=66               N=631                          N=604
                                                                                                                                                         
  ALT increased                                            9 (16.7)                                    11 (16.7)          1 (0.2)                        12 (2.0)
                                                                                                                                                         
  AST increased                                            7 (13.0)                                    5 (7.6)            7 (1.1)                        14 (2.3)
                                                                                                                                                         
  Hyperbilirubinaemia                                      0                                           0                  4 (0.6)                        1 (0.2)

ITT-TLOVR = intent-to-treat-time-to-loss of virologic response; CI=confidence interval; \*Patients included in efficacy analysis were those with baseline HBV/HCV assessments; †NC=F = non completer = failure: missing values after discontinuation imputed with change = 0; Last observation carried forward otherwise; ‡Safety analyses performed using all available data, including beyond Week 48; §Patients who seroconverted for HBV/HCV during the study were included in the subgroup of HIV/HBV and/or HCV co-infected patients; Â¶Selection of preferred terms from System Organ Class as defined by MedDRA. Compared with HIV mono-infected patients, co-infected patients had more hepatic AEs (clinical and laboratory) and lower virologic responses, which were similar across treatment groups. Hepatic AEs rarely led to treatment discontinuation (TMC278: n=3 vs. EFV: n=9 patients). There were no fatal hepatic AEs.

Conclusions
===========

Overall, both TMC278 and EFV were well tolerated with no hepatic safety differences observed. Hepatic AEs were more common in co-infected than in HIV mono-infected patients (27% vs. 4%, respectively), but there were no differences between the two treatment groups. Virologic responses were similar for TMC278 and EFV within the co-infected and HIV mono-infected groups, and lower in co-infected than in HIV mono-infected patients.
